Emi-Le
Emi-Le is an investigational product that has demonstrated early anti-tumor activity in an ongoing Phase 1 study for adenoid cystic carcinoma (ACC), a cancer with high unmet need and lack of therapeutic options.
Emi-Le (emiltatug ledadotin) is an investigational B7-H4-targeted ADC with a precise, target-optimized drug-to-antibody ratio (DAR 6) and a proprietary payload. B7-H4 is highly expressed in ACC as well as in other adult and pediatric cancers.
A multicenter Phase 1 trial was opened in 2022 to investigate the safety, tolerability and anti-tumor activity of Emi-Le in patients with solid tumors, including ACC, breast, endometrial and ovarian cancers. In the initial clinical data reported from Phase 1, Emi-Le was observed to be generally well tolerated and confirmed objective responses were observed across multiple tumor types.
A multicenter Phase 1 trial was opened in 2022 to investigate the safety, tolerability and anti-tumor activity of Emi-Le in patients with solid tumors, including ACC, breast, endometrial and ovarian cancers. In the initial clinical data reported from Phase 1, Emi-Le was observed to be generally well tolerated and confirmed objective responses were observed across multiple tumor types.